Fidelity Investments
VTGN icon

Fidelity Investments’s VistaGen Therapeutics VTGN Stock Holding History

Fidelity Investments’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed -$75 – 5830
2024
Q3 		$75 Sell
25
-4,121
-99% -$14.1K ﹤0.01% 5125
2024
Q2 		$14.4K Buy
+4,146
New +$18K ﹤0.01% 4188
2023
Q3 		– Sell
-1,936
Closed -$3.62K – 5543
2023
Q2 		$3.62K Sell
1,936
-475
-20% -$1.67K ﹤0.01% 4454
2023
Q1 		$9.02K Buy
2,411
+1,346
+126% +$7.06K ﹤0.01% 4165
2022
Q4 		$3.29K Sell
1,065
-4,999
-82% -$18.8K ﹤0.01% 4379
2022
Q3 		$28K Buy
6,064
+5,852
+2,760% +$58K ﹤0.01% 3719
2022
Q2 		$5K Buy
212
+189
+822% +$6.67K ﹤0.01% 4335
2022
Q1 		$0 Buy
23
+9
+64% +$392 ﹤0.01% 5528
2021
Q4 		$1K Buy
+14
New +$911 ﹤0.01% 4214
2021
Q3 		– Sell
-83
Closed -$7.21K – 5102
2021
Q2 		$8K Buy
+83
New +$6.15K ﹤0.01% 3615

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments's VTGN Position: Q4 2024 in Review

Fidelity Investments sold out of VistaGen Therapeutics (VTGN) in Q4 2024, closing a stake of 25 shares — an estimated $75 sold.

Fidelity Investments first reported a position in VTGN in Q2 2021 and held it in 10 quarters. The position peaked at $28K in Q3 2022. 54 funds tracked by Wall St. Rank hold VTGN as of Q4 2024.

  • Fidelity Investments reported no remaining VistaGen Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fidelity Investments sold 25 VistaGen Therapeutics shares in Q4 2024, an estimated $75.
  • Fidelity Investments first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 10 quarters.
  • Fidelity Investments's VistaGen Therapeutics position peaked at $28K in Q3 2022.
  • 54 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2024.

Based on Fidelity Investments's 13F filing for Q4 2024, filed 13 Feb 2025.